

ESPI current report

Number: 6/2026
Date of preparation February 12, 2026
Company Genomtec SA based in Wrocław

Title	Information on the commencement of preparatory activities related to the planned testing of Genomtec technology in Asia.
--------------	---

Legal basis: Article 17(1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council (MAR)

Content of the Report: The Management Board of Genomtec S.A. (the "Company") hereby announces that as part of the M&A process, on February 12, 2026, the Company decided to initiate preparatory activities of an organizational and analytical nature related to the planned testing of Genomtec diagnostic devices at selected entities from the Asian region, being potential partners who reported the need to conduct these tests during the talks.

Analyses conducted by the Company show that the molecular and oncological diagnostics market in Asia is growing faster than in Europe or the USA, therefore, in the Issuer's opinion, it is justified to take steps to seek investors from this market as well.

The actions taken include in particular:

- determining with the interested parties the scope and method of conducting local tests by Genomtec staff,
- analysis of the available time frames for their implementation and logistical conditions,
- assessment of legal requirements, including in particular biosafety, that apply to the implementation of tests in a given region,
- preparation for production and production of the appropriate number of reaction cards needed to carry out the tests.

These activities are of a preparatory nature and do not imply a final decision on establishing commercial cooperation or implementing any transactions, including M&A or other business transactions with the Company, and the actual commencement of tests is dependent on the successful implementation of the activities indicated above.

As of the date of publication of this report, the Company has not concluded any agreements or contracts in this respect, and the Company will inform about the next significant stages related to the planned tests in the Asian region in the appropriate reports.

Signatures of persons representing the Company:

Michał Wachowski - Member of the Management Board